Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors

SAR and QSAR in Environmental Research

Volumn 21, Issue 1-2, 2010, Pages 1-20

  Saxena, A K ^a   Saxena, S ^a   Chaudhaery, S S ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Conserved; GOLD; Hsp90; Hypogen; Pharmacophore

Indexed keywords

BINDING ENERGY; BIOACTIVITY; CELL DEATH; COMPLEXATION; GOLD; PROTEINS; SIGNAL TRANSDUCTION; SOFTWARE TESTING;

CONSERVED; DOCKING STUDIES; GOLD; GOOD CORRELATIONS; HEAT-SHOCK PROTEIN 90; HYPOGEN; MOLECULAR MODELING STUDIES; PHARMACOPHORE MODELS; PHARMACOPHORES; TEST SETS;

HYDROGEN BONDS;

RUMEX;

EID: 77951446075     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/10629360903560504     Document Type: Article

References (24)

1. J. Dajorath, T.E. Klein, T.P. Lybrand, and J. Novotny, Computer aided drug discovery: from target properties to drug candidates, Pac. Symp. Biocomputing 4 (1997), pp. 413-414.
2. P. Prathaipati, A. Dixit, and A.K. Saxena, Computer-aided drug design: integration of structure-based and ligand based approaches in drug design, Curr. Comput. Aided Drug Des. 3 (2007), pp. 341-352.
3. P. Csermely, T. Schnaider, C. Soti, Z. Prohaszka, and G. Nardai, The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review, Pharmacol. Ther. 79 (1998), pp. 129-168.
4. K. Richter and J. Buchner, Hsp90: chaperoning signal transduction, J. Cell. Physiol. 188 (2001), pp. 281-290.
5. S. Sharp and P. Workman, Inhibitors of the Hsp90 molecular chaperone. Current status, Adv. Cancer Res. 95 (2006), pp. 323-348.
6. L. Neckers and S.P. Ivy, Heat shock protein 90, Curr. Opin. Oncol. 15 (2003), pp. 419-424.
7. P. Fortugno, E. Beltrami, J. Plescia, J. Fontana, D. Pradhan, P.C. Marchisio, W.C. Sessa, and D.C. Altieri, Regulation of survivin function by Hsp90, Proc. Natl. Acad. Sci. USA 100 (2003), pp. 13791-13796.
8. M.G. Marcu, T.W. Schulte, and L.J. Neckers, Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins, Natl. Cancer Inst. 92 (2000), pp. 242-248.
9. G. Chiosis, M. Vilenchik, J. Kim, and D. Solit, Hsp90: the vulnerable chaperone, Drug Discov. Today 9 (2004), pp. 881-888.
10. Y.L. Janin, Heat shock protein 90 inhibitors, J. Med. Chem. 48 (2005), pp. 7503-7512.
11. H. Fujiwara, T. Yamakuni, M. Ueno, M. Ishizuka, T. Shinkawa, T. Isobe, and Y. Ohizumi, IC101 induces apoptosis by Akt dephosphorylation via an inhibition of heat shock protein 90-ATP binding activity accompanied by preventing the interaction with Akt in L1210 cells, J. Pharmacol. Exp. Ther. 310 (2004), pp. 1288-1295.
12. L. Zhang, J. Fan, K. Vu, K. Hong, J.Y.L. Brazidec, J. Shi, M. Biamonte, D.J. Busch, R.E. Lough, R. Grecko, Y. Ran, J.L. Sensintaffar, A. Kamal, K. Lundgren, J. Francis, R.M. Burrows, G.A. Timony, E.H. Ulm, S.R. Kasibhatla, and M.F. Boehm, 7′-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors, J. Med. Chem. 49 (2006), pp. 5352-5362.
13. P.A. Brough, X. Barril, M. Beswick, B.W. Dymock, M.J. Drysdale, L. Wright, K. Grant, A. Massey, A. Surgenora, and P. Workman, 3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone, Bioorg. Med. Chem. Lett. 15 (2005), pp. 5197-5201.
14. X. Barril, P. Brough, M. Drysdale, R.E. Hubbard, A. Massey, A. Surgenor, and L. Wright, Structure-based discovery of a new class of Hsp90 inhibitors, Bioorg. Med. Chem. Lett. 15 (2005), pp. 5187-5191.
15. B.W. Dymock, X. Barril, P.A. Brough, J.E. Cansfield, A. Massey, E. McDonald, R.E. Hubbard, A. Surgenor, S.D. Roughley, P. Webb, P. Workman, L. Wright, and M.J. Drysdale, Novel, Potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design, J. Med. Chem. 48 (2005), pp. 4212-4215.
16. P.A. Brough, W. Aherne, X. Barril, J. Borgognoni, K. Boxall, J.E. Cansfield, K.M.J. Cheung, I. Collins, N.G.M. Davies, M.J. Drysdale, B. Dymock, S.A. Eccles, H. Finch, A. Fink, A. Hayes, R. Howes, R.E. Hubbard, K. James, A.M. Jordan, A. Lockie, V. Martins, A. Massey, T.P. Matthews, E. McDonald, C.J. Northfield, L.H. Pearl, C. Prodromou, S. Ray, F.I. Raynaud, S.D. Roughley, S.Y. Sharp, A. Surgenor, D.L. Walmsley, P. Webb, M. Wood, P. Workman, and L. Wright, 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer, J. Med. Chem. 51 (2008), pp. 196-218.
17. X. Barril, M.C. Beswick, A. Collier, M.J. Drysdale, B.W. Dymock, A. Fink, K. Grant, R. Howes, A.M. Jordan, A. Massey, A. Surgenor, J. Wayne, P. Workmanb, and L. Wright, 4-Amino derivatives of the Hsp90 inhibitor CCT018159, Bioorg. Med. Chem. Lett. 16 (2006), pp. 2543-2548.
18. Discovery studio 2.0 User Guide, Accelrys Inc., San Diego, CA.
19. T. Equbal, O. Silakari, G. Rambabub, and M. Ravikumarb, Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors, Bioorg. Med. Chem. Lett. 17 (2007), pp. 1594-1600.
20. GOLD, version 3.2; Cambridge Crystallographic Data Centre, Cambridge, UK.
21. ClustalW2. Available at http://www.ebi.ac.uk/Tools/clustalw2/index.html
22. F. Liu, Q.D. You, and Y.D. Chen, Pharmacophore identification of KSP inhibitors, Bioorg. Med. Chem. Lett. 17 (2007), pp. 722-726.
23. C.E. Stebbins, A.A. Russo, K.C. Schneider, N. Rosen, F.U. Hartl, and N.P. Pavletich, Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor Agent, Cell 89 (1997), pp. 239-250.
24. UniProt. Available at http://www.uniprot.org